Posttranscriptional regulation of T-cell IL-2 production by human pooled immunoglobin

Clin Immunol Immunopathol. 1997 Apr;83(1):77-85. doi: 10.1006/clin.1997.4329.


We evaluated the mechanism by which human pooled gamma-globulin for intravenous use (hIVIG) inhibits interleukin-2 (IL-2) production by human T cells. hIVIG reduced by 70-95% the amount of IL-2 in culture supernatants from mitogen-stimulated peripheral blood T cells or Jurkat cells. This reduction was not apparent at the transcriptional level: hIVIG had no effect on the levels of IL-2 mRNA or on the accumulation of firefly luciferase when its gene was linked to the IL-2 promoters. In contrast, hIVIG inhibited IL-2 protein synthesis, and the intracellular IL-2 was not restored by monensin. Our results indicate that the inhibition of IL-2 production by hIVIG occurred post-transcriptionally, and also suggest that secretion was unaffected, and that this effect of hIVIG was specific for IL-2 (and possibly other related cytokines). The data identify a previously uncharacterized regulatory mechanism of IL-2 production and predict that this immunomodulatory effect of hIVIG may be significant for its therapeutic actions in immune-mediated diseases.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Cells, Cultured
  • Gene Expression Regulation
  • Humans
  • Immunoglobulins, Intravenous / genetics*
  • Immunoglobulins, Intravenous / pharmacology
  • Interleukin-2 / biosynthesis*
  • Interleukin-2 / genetics*
  • Promoter Regions, Genetic / drug effects
  • RNA Processing, Post-Transcriptional
  • RNA, Messenger / metabolism
  • T-Lymphocytes / metabolism*


  • Immunoglobulins, Intravenous
  • Interleukin-2
  • RNA, Messenger